35.28
전일 마감가:
$34.55
열려 있는:
$33.95
하루 거래량:
640.38K
Relative Volume:
0.94
시가총액:
$2.17B
수익:
$87.56M
순이익/손실:
$-167.47M
주가수익비율:
-15.08
EPS:
-2.34
순현금흐름:
$-148.20M
1주 성능:
+6.07%
1개월 성능:
+33.84%
6개월 성능:
-24.08%
1년 성능:
-2.81%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
KYMR
Kymera Therapeutics Inc
|
35.28 | 2.17B | 87.56M | -167.47M | -148.20M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-13 | 개시 | Citigroup | Buy |
2024-12-10 | 개시 | BTIG Research | Buy |
2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2024-11-18 | 개시 | Stephens | Overweight |
2024-09-09 | 재개 | Leerink Partners | Outperform |
2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2024-04-22 | 개시 | Oppenheimer | Outperform |
2024-02-15 | 개시 | Wolfe Research | Peer Perform |
2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2023-06-30 | 개시 | Truist | Buy |
2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2022-11-08 | 개시 | Raymond James | Mkt Perform |
2022-08-15 | 개시 | Jefferies | Buy |
2022-08-03 | 개시 | Goldman | Buy |
2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
2022-04-28 | 개시 | Credit Suisse | Outperform |
2022-03-10 | 개시 | JP Morgan | Neutral |
2022-02-10 | 개시 | Wells Fargo | Overweight |
2021-09-30 | 개시 | B. Riley Securities | Neutral |
2021-09-30 | 개시 | Stifel | Buy |
2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
2021-05-21 | 개시 | UBS | Buy |
2021-04-14 | 개시 | Berenberg | Buy |
2020-12-04 | 개시 | H.C. Wainwright | Buy |
2020-09-15 | 개시 | BofA Securities | Neutral |
2020-09-15 | 개시 | Cowen | Outperform |
2020-09-15 | 개시 | Guggenheim | Buy |
2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics Inc’s results are impressive - uspostnews.com
Market Momentum Report: Kymera Therapeutics Inc (KYMR)’s Positive Close at 34.55 - DWinneX
Invesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Closing Figures Unveiled: Kymera Therapeutics Inc (KYMR) Drop -7.60, Closes at 27.37 - DWinneX
JPMorgan Chase & Co. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Why Kymera Therapeutics (KYMR) Stock is Moving Today - GuruFocus
Why Kymera Therapeutics Stock Crushed it This Week - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Kymera Therapeutics Inc [KYMR] Shares Rise 9.32 % on Thursday - knoxdaily.com
KYMR’s Stock Market Adventure: -16.58% YTD Growth Amidst Volatility - investchronicle.com
Daily Market Movement: Kymera Therapeutics Inc (KYMR) Sees a 9.32 Increase, Closing at 33.56 - DWinneX
Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 F - GuruFocus
Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 Financials | KYMR Stock News - GuruFocus
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 - The Manila Times
Kymera Unveils Revolutionary Oral Drug Program Targeting Untapped Autoimmune Disease Pathway - Stock Titan
Is Kymera Therapeutics Inc (KYMR) worth investing in despite its overvalued state? - uspostnews.com
Kymera Therapeutics (KYMR) Begins Phase 1b Trial for Atopic Dermatitis Treatment | KYMR Stock News - GuruFocus
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader - The Manila Times
Breakthrough Oral Treatment for Eczema: First Patient Receives New STAT6 Degrader Drug in Clinical Trial - Stock Titan
Kymera Therapeutics Inc (KYMR) Stock: A Year of Declines and Increases - investchronicle.com
Learn to Evaluate (KYMR) using the Charts - news.stocktradersdaily.com
Investor’s Delight: Kymera Therapeutics Inc (KYMR) Closes Strong at 33.27, Up 0.76 - DWinneX
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Consensus Target Price from Analysts - Defense World
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? - MSN
Kymera Therapeutics Appoints Noah Goodman as Chief Business Offi - GuruFocus
Kymera Therapeutics appoints new Chief Business Officer - Investing.com Australia
Kymera Therapeutics appoints new Chief Business Officer By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - citybiz
Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan
Kymera stock touches 52-week low at $20.77 amid market challenges - Investing.com Australia
Kymera stock touches 52-week low at $20.77 amid market challenges By Investing.com - Investing.com South Africa
Vanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
(KYMR) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia
Kymera Therapeutics identifies new STAT6 degraders - BioWorld MedTech
Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada
Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - The AM Reporter
Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq
Citigroup starts coverage of Kymera with $52 PT - TradingView
(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Why Kymera Therapeutics’ Stock is Making Waves - TipRanks
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):